Abstract
The involvement of the caudate nucleus, i.e., the terminal zone of the nigrostriatal dopaminergic system, in neuroimmunostimulation during the activation of μ opioid receptors by the highly specific agonist DAGO. Single doses of DAGO (100 μg/kg) in sham-operated control Wistar rats induced significant increases in the numbers of direct IgM-antibody-forming and total rosette-forming cells at the peak of the immune response after immunization with sheet red blood cells. The experiments showed that bilateral electrolytic lesioning of the caudate nucleus in rats suppressed the immune response, demonstrating its involvement in neuroimmunomodulation. Since the effect of immunostimulation induced by DAGO disappeared when given to animals with caudate nucleus lesions, it was concluded that this structure is involved in activatory immunogenesis via μ opioid mechanisms.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
L. V. Devoino and R. Yu. Il'yuchenok, Monoaminergic Systems in the Regulation of Immune Responses [in Russian], Nauka, Novosibirsk (1983).
M. A. Cheido, G. V. Idova, and L. V. Devoino, “Serotonin-dependent suppression of the immune response by kappa-opiate receptors,” Byull. Éksp. Biol. Med., 9, 291–292 (1993).
M. A. Cheido and G. V. Idova, “Dopaminergic mechanisms in the immunostimulating effect of ??opiate receptors,” Byull. Éksp. Biol. Med., 4, 373–375 (1996).
M. A. Cheido and G. V. Idova, “The effects of opioid peptides on the process of immunomodulation,” Ros. Fiziol. Zh. im. I. M. Sechenova, 84, No. 4, 385–390 (1998).
J. H. Bublik and J. W. Funder, “Interaction of dopamine receptor ligands with subtypes of the opiate receptor,” Eur. J. Pharmacol., 107, 11–16 (1985).
M. Cheido, G. Idova, and L. Devoino, “Involvement of delta-opioid receptors in immunosuppressive,” Intern. J. Neurosci., 84, 195–203 (1996).
A. J. Cunningham, “A method of increased sensitivity for detecting single antibody-forming cells,” Nature, 207, 1106–1107 (1965)
L. V. Devoino, L. S. Eliseeva, G. V. Idova, and M. A. Cheido, “5-Hydroxytryptophan effect on the development of the immune response: IgM-and IgG-antibodies and rosette formation in primary and secondary responses,” Eur. J. Immunol., 5, 394–399 (1975).
L. Devoino, E. Alperina, O. Galkina, and R. Ilyutchenok, “Involvement of brain dopaminergic structures in neuroimmunomodulation,” Intern. J. Neurosci., 93, No. 3<4, 213–228 (1997).
Y. Q. Ding, T. Kaneko, S. Nomura, and N. Mizuno, “Immmunohistochemical localization of mu-opioid receptors in the central nervous system of the rat,” J. Comp. Neurol., 367, No. 3, 375–402 (1996).
N. Dourmap, E. Clero, and J. Costenin, “Involvement of cholinergic neurons in the release of dopamine elicited by stimulation of mu-opioid receptors in striatum,” Brain Res., 749, No. 2, 295–300 (1997).
E. Hamel and A. Beandet, “Ultrastructural distribution of mu-opioid receptors in rat neostriatum,” in: Neurotransmitter Interactions in the Basal Ganglia, M. Sandler et al. (eds.), Raven Press, New York (1987), pp. 59–69.
B. K. Handa, A. C. Lane, J. A. H. Lord, B. A. Morgan, M. J. Rance, and C. F. C. Smith, “Analogues of ?-LPH61-64 possessing selective agonist activity at ?-opiate receptors,” Eur. J. Pharmacol., 70, 531–540 (1981).
Z. S. Herman, M. Huzarska, K. Kmieciak-Kolada, and J. Kowalski, “Chronic treatment with chlorpromazine, thioridazine or haloperidol increases striatal enkephalins and their release from brain,” Psychopharmacology, 104, 106–112 (1991).
C. A. Ingham, S. H. Hood, and G. W. Arbuthnott, “A light and electron microscopical study of enkephalin < immunoreactive structures in the rat neostriatum after removal of the nigrostriatal dopaminergic pathway,” Neurosci., 42, No. 3, 715–730 (1991).
I. F. James and A. Gololtein, “A site-directed alkylation of multiple opioid receptor,” Mol. Pharmacol., 25, 337–342 (1984).
P. W. Kalivas and P. Duffy, “Effect of acute and daily neurotensin and enkephalin and enkephalin treatments on extracellular dopamine in the nucleus accumbens,” J. Neurosci., 10, 2940–2949 (1990).
K. Kamata, “Pharmacological studies on the interrelation between the dopaminergic, GABA-ergic, and opioid peptidergic systems in the central nervous system of the rat,” Japan J. Pharmacol., 45,. 439–447 (1987).
T. Kaneko, M. Minami, M. Satoh, and N. Mizuno, “Immunocytochemical localization of ?-opioid receptors in the brain caudaten-putamen,” Neurosci. Lett., 184, 149–152 (1995).
J. F. R. Konig and R. A. Klippel, The Rat Brain. A Stereotaxic Atlas of the Forebrain and Lower Parts of the Brain Stem, Baltimore (1963).
L. G. Latimer, P. Duffy, and P. W. Kalivas, “Mu-opioid receptor involvement in enkephalin activation of dopamine neurons in the ventral tegmental area,” J. Pharmacol. Ther., 241, 328–337 (1987).
B. Levant and N. R. Vansell, “In vivo occupancy of D2 dopamine receptors by nafadotride,” Neuropsychopharmacology, 17, 67–71 (1997).
A. Mansour, C. A. Fox, S. Burke, H. Acil, and S. J. Watson, “Immunohistochemical localization of the cloned mu-opioid receptor in the rat CNS,” J. Chem. Neuroanatomy, 8, 283–305 (1995).
J. F. Marshall, S. J. O'Dell, R. Navarette, and A. J. Rosenstein, “Dopamine high-affinity transport density topography in rat brain: major differences between dorsal and ventral striatum,” Neuroscience, 37, No. 1, 11–21 (1990).
L. Perez and D. T. Lysle, “Conditioned immunomodulation: investigations of the role of endogenous activity at mu-, kappa-and delta-opioid receptor subtypes,” J. Neuroimmunol., 79, No. 2, 101–112 (1997).
V. M. Pickel, J. Chan, and S. R. Sesack, “Cellular basis for interactions between catecholaminergic afferents and leuenkephalins-like immunoreactivity in rat caudate-putamen,” J. Neurosci. Res., 31, 212–230 (1992).
J. Radulovic and B. D. Jankovic, “Opposing activities of brain opioid receptors in the regulation of humoral and cell-mediated immune responses in the rat,” Brain Res., 661, 189–195 (1994).
D. D. Taub, T. K. Eisenstein, E. B. Geller, M. W. Adler, and T. J. Rogers, “Immunomodulatory activity of mu-and kappa-selective opioid agonists,” Proc. Natl. Acad. Sci. USA, 88, 360–364 (1991).
M. Ukai, T. Tojoshi, and T. Kameyama, “DAGO ([d-Ala, N-Me-Phe4, Gly-ol] enkephalin) specifically reverses apomorphine-induced increase in rearing and grooming behaviors in the mouse,” Brain Res., 557, 77–82 (1991).
B. K. Yamamoto and L. J. Spanos, “The acute effects of methylenedioxymethane phetamine on dopamine release in the awake-behaving rat,” Eur. J. Pharmacol., 48, 195–203 (1988).
N. Yanehara, G. di Chiara, and D. H. Clonet, “Effects of delta and mu opiopeptides on the turnover and release of dopamine in rat striatum,” J. Pharmacol. Exp. Ther., 231, 38–42 (1984).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Devoino, L.V., Cheido, M.A. & Al'perina, E.L. Involvement of the Rat Caudate Nucleus in the Immunostimulatory Effect of Dago. Neurosci Behav Physiol 31, 323–326 (2001). https://doi.org/10.1023/A:1010394820455
Issue Date:
DOI: https://doi.org/10.1023/A:1010394820455